Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas

Neuro-Oncology

Volumn 16, Issue 9, 2014, Pages 1196-1209

  Boin, Alizée ^a   Couvelard, Anne ^g,h   Couderc, Christophe ^a   Brito, Isabel ^b   Filipescu, Dan ^e   Kalamarides, Michel ^b,f,h   Bedossa, Pierre ^f   De Koning, Leanne ^d   Danelsky, Carine ^d   Dubois, Thierry ^d   Hupé, Philippe ^b,c   Louvard, Daniel ^a   Lallemand, Dominique ^a  

^a INSTITUT CURIE   (France)

^b INSERM   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d INSTITUT CURIE   (France)

^e CNRS   (France)

^f BEAUJON HOSPITAL   (France)

^g BICHAT HOSPITAL   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Neurofibromatosis type 2; Proteomic; Schwannoma; Signaling; YAP

Indexed keywords

ANGIOPOIETIN RECEPTOR; CATENIN; EPHRIN RECEPTOR B2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GLYCOGEN SYNTHASE KINASE 3BETA; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN AXL; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; PROTEIN P46; PROTEIN P55; PROTEIN RET; PROTEIN TYROSINE KINASE; SOMATOMEDIN C; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ARTICLE; CELL MEMBRANE; CELL PROLIFERATION; CORRELATION ANALYSIS; CYTOPLASM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOGENESIS; MOLECULARLY TARGETED THERAPY; NEURILEMOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTEOMICS; SAMPLE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CELL; WNT SIGNALING PATHWAY; BRAIN TUMOR; METABOLISM; NEUROFIBROMATOSIS TYPE 2;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BRAIN NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; MALE; NEURILEMMOMA; NEUROFIBROMATOSIS 2; PHOSPHOPROTEINS; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 84907006005     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou020     Document Type: Article

References (49)

1. Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet. 2009;373(9679):1974-1986.
2. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993;363(6429):515-521. (Pubitemid 23186636)
3. Morrison H, Sperka T, Manent J, et al. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res. 2007;67(2):520-527. (Pubitemid 46192188)
4. Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 2001;1(1):63-72. (Pubitemid 33586069)
5. Curto M, Cole BK, Lallemand D, et al. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol. 2007;177(5):893-903. (Pubitemid 46873094)
6. Maitra S, Kulikauskas RM, Gavilan H, et al. The tumor suppressors Merlin and Expanded function cooperatively to modulate receptor endocytosis and signaling. Curr Biol. 2006;16(7):702-709.
7. Lallemand D, Curto M, Saotome I, et al. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 2003;17(9):1090-1100. (Pubitemid 36534984)
8. Li W, You L, Cooper J, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell. 2010;140(4):477-490.
9. Hamaratoglu F, Willecke M, Kango-Singh M, et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol. 2006;8(1):27-36. (Pubitemid 43064794)
10. Yu J, Zheng Y, Dong J, et al. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell. 2010;18(2):288-299.
11. Zhang N, Bai H, David KK, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell. 2010;19(1):27-38.
12. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747-2761. (Pubitemid 350070721)
13. Zhao B, Kim J, Ye X, et al. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res. 2009;69(3):1089-1098.
14. Ammoun S, Hanemann CO. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol. 2011;7(7):392-399.
15. Kaempchen K, Mielke K, Utermark T, et al. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet. 2003;12(11):1211-1221. (Pubitemid 36722601)
16. Ammoun S, Provenzano L, Zhou L, et al. Axl/Gas6/NFkB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene. 2013;33(3):336-346.
17. Hilton DA, Ristic N, Hanemann CO. Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology. 2009;55(6):744-749.
18. Hansen MR, Linthicum FH Jr. Expression of neuregulin and activation of erbB receptors in vestibular schwannomas: possible autocrine loop stimulation. Otol Neurotol. 2004;25(2):155-159. (Pubitemid 39079844)
19. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd., et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358-367.
20. Gujral TS, Karp RL, Finski A, et al. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene. 2012;32(29):3470-3476.
21. Scoles DR, Nguyen VD, Qin Y, et al. Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet. 2002;11(25):3179-3189. (Pubitemid 35439430)
22. James MF, Han S, Polizzano C, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009;29(15):4250-4261.
23. Bosco EE, Nakai Y, Hennigan RF, et al. NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene. 2010;29(17):2540-2549.
24. Hao Y, Chun A, Cheung K, et al. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem. 2008;283(9):5496-5509.
25. Xu MZ, Chan SW, Liu AM, et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 2011;30(10):1229-1240.
26. Zhao B, Ye X, Yu J, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962-1971. (Pubitemid 352008643)
27. Hung G, Li X, Faudoa R, et al. Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol. 2002;20(3):475-482.
28. Doherty JK, Ongkeko W, Crawley B, et al. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy. Otol Neurotol. 2008;29(1):50-57.
29. Ammoun S, Cunliffe CH, Allen JC, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol. 2010;12(8):834-843.
30. Hansen MR, Roehm PC, Chatterjee P, et al. Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. Glia. 2006;53(6):593-600.
31. Hynes NE, Horsch K, Olayioye MA, et al. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer. 2001;8(3):151-159. (Pubitemid 32947637)
32. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039-1043. (Pubitemid 46799492)
33. Moriyama T, Kataoka H, Kawano H, et al. Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans. Cancer Lett. 1998;124(2):149-155. (Pubitemid 28073681)
34. Torres-Martin M, Lassaletta L, San-Roman-Montero J, et al. Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation. Int J Oncol. 2013;42(3):848-862.
35. Wickremesekera A, Hovens CM, Kaye AH. Expression of ErbB-1 and 2 in vestibular schwannomas. J Clin Neurosci. 2007;14(12):1199-1206. (Pubitemid 350102794)
36. Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010;31(7):1135-1143.
37. Karajannis MA, Legault G, Hagiwara M, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 2012;14(9):1163-1170.
38. Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33(6):1046-1052.
39. Verma A, Warner SL, Vankayalapati H, et al. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther. 2011;10(10):1763-1773.
40. Li R, Chen J, Hammonds G, et al. Identification of Gas6 as a growth factor for human Schwann cells. J Neurosci. 1996;16(6):2012-2019. (Pubitemid 26146712)
41. Li Y, Ye X, Tan C, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 2009;28(39):3442-3455.
42. Hashizume H, Falcón BL, Kuroda T, et al. Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth. Cancer Res. 2010;70(6):2213-2223.
43. Gujral TS, Karp RL, Finski A, et al. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene. 2012;32(29):3470-3476.
44. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007;251(2):199-210. (Pubitemid 46680370)
45. Pectasides E, Egloff AM, Sasaki C, et al. Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res. 2010;16(8):2427-2434.
46. Zhao B, Li L, Tumaneng K, et al. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFβ-TRCP. Genes Dev. 2010;24(1):72-85.
47. Nguyen HB, Babcock JT, Wells CD, et al. LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap. Oncogene. 2012;32(35):4100-4109.
48. Lallemand D, Manent J, Couvelard A, et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene. 2009;28(6):854-865.
49. Troncale S, Barbet A, Coulibaly L, et al. NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data. PLoS One. 2012;7(6):e38686.